Stockscreener 앱 받기
2.04
0.99%
0.02
전일 마감가:
$2.02
열려 있는:
$1.98
하루 거래량:
4,336
Relative Volume:
0.18
시가총액:
$23.50M
수익:
$3.02M
순이익/손실:
$-653.00K
주가수익비율:
-41.38
EPS:
-0.0493
순현금흐름:
$2.42M
1주 성능:
+1.49%
1개월 성능:
-3.32%
6개월 성능:
+4.08%
1년 성능:
+39.73%
1일 변동 폭
$1.98
$2.0398
1주일 범위
$1.93
$2.10
52주 변동 폭
$0.9811
$2.95
Therapeuticsmd Inc Stock (TXMD) Company Profile
명칭
Therapeuticsmd Inc
전화
561-961-1900
주소
951 YAMATO ROAD, SUITE 220, BOCA RATON, FL
Compare TXMD vs TAK, TEVA, HLN, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TXMD
Therapeuticsmd Inc
|
2.03 | 23.38M | 3.02M | -653.00K | 2.42M | -0.0493 |
TAK
Takeda Pharmaceutical Co Adr
|
16.64 | 52.58B | 29.85B | 776.90M | 4.35B | 0.2408 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.38 | 42.21B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
8.965 | 39.99B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
75.36 | 31.17B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
572.65 | 24.60B | 3.17B | 1.29B | 1.01B | 27.09 |
Therapeuticsmd Inc Stock (TXMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-08-07 | 다운그레이드 | Jefferies | Hold → Underperform |
| 2020-05-19 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-12-02 | 개시 | Guggenheim | Buy |
| 2019-10-17 | 개시 | H.C. Wainwright | Buy |
| 2019-04-30 | 재개 | Noble Capital Markets | Outperform |
| 2018-06-15 | 개시 | JP Morgan | Overweight |
| 2017-09-08 | 개시 | Morgan Stanley | Equal-Weight |
| 2017-07-11 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2017-05-09 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2016-11-22 | 재개 | Jefferies | Buy |
| 2016-11-22 | 개시 | Oppenheimer | Outperform |
| 2016-11-07 | 재개 | Guggenheim | Buy |
| 2016-04-04 | 개시 | Goldman | Buy |
| 2015-12-08 | 재확인 | Jefferies | Buy |
| 2015-12-08 | 재확인 | Stifel | Buy |
| 2015-09-21 | 재확인 | Jefferies | Buy |
| 2015-06-09 | 개시 | Guggenheim | Buy |
| 2014-07-08 | 개시 | FBR Capital | Outperform |
| 2014-04-17 | 재확인 | Noble Financial | Buy |
| 2014-01-28 | 재확인 | Noble Financial | Buy |
모두보기
Therapeuticsmd Inc 주식(TXMD)의 최신 뉴스
TherapeuticsMD Inc. stock outperforms competitors on strong trading day - MarketWatch
TherapeuticsMD Announces First Quarter 2026 Financial Results - BioSpace
TXMD Reports Strong Q1 Revenue Growth and Explores Strategic Alt - GuruFocus
Is TherapeuticsMD (TXMD) 13.4% Overvalued After Q1 2026 Earnings - GuruFocus
[10-Q] TherapeuticsMD, Inc. Quarterly Earnings Report - Stock Titan
TherapeuticsMD Reports Quarterly Profit, Evaluates Strategic Alternatives - TipRanks
TherapeuticsMD: Q1 Earnings Snapshot - marketscreener.com
TherapeuticsMD swings to Q1 net income as license revenue rises - TradingView
TherapeuticsMD (TXMD) details Q1 2026 results and strategic review - Stock Titan
TherapeuticsMD Inc. stock underperforms Monday when compared to competitors - MarketWatch
TherapeuticsMD Inc. stock underperforms Friday when compared to competitors - MarketWatch
TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
TXMD Stock Price, Quote & Chart | THERAPEUTICSMD INC (NASDAQ:TXMD) - ChartMill
TherapeuticsMD Inc. stock underperforms Thursday when compared to competitors - MarketWatch
TXMD Should I Buy - Intellectia AI
TXMD (TherapeuticsMD Inc.) posts far wider Q3 2023 loss than expected, with shares dipping 0.48% in today’s trading.Stock Community Signals - Cổng thông tin điện tử tỉnh Tây Ninh
TXMD (TherapeuticsMD Inc.) Q3 2023 EPS misses consensus estimates by wide margin as shares dip 0.48 percent in today's trading.Trending Stock Ideas - Cổng thông tin điện tử tỉnh Tây Ninh
Form 10-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]: [Amend] - ADVFN
Total debt per share of TherapeuticsMD, Inc. – MUN:29TA - TradingView — Track All Markets
TherapeuticsMD Inc. stock rises Wednesday, still underperforms market - MarketWatch
TherapeuticsMD Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
[SCHEDULE 13G] TherapeuticsMD, Inc. Passive Investment Disclosure (>5%) - Stock Titan
Profit Recap: Is TherapeuticsMD Inc stock a buy or sell2026 Review & Real-Time Volume Trigger Notifications - baoquankhu1.vn
TherapeuticsMD Inc. (TXMD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
TherapeuticsMD Inc. R (29TA.F) stock price, news, quote and history - Yahoo Finance UK
TherapeuticsMD Explains Brief Delay In Annual Filing - The Globe and Mail
TherapeuticsMD 2025 Annual Report: Business Overview, Risk Factors, and Intellectual Property Challenges - Minichart
[10-K/A] TherapeuticsMD, Inc. Amends Annual Report - Stock Titan
TherapeuticsMD Inc. stock rises Tuesday, still underperforms market - MarketWatch
TherapeuticsMD, Inc. (TXMD) stock price, news, quote and history - Yahoo Finance UK
TherapeuticsMD Announces Full Year 2025 Financial Results - BioSpace
TherapeuticsMD (NASDAQ: TXMD) files 2025 Form 10-K after printer error - Stock Titan
TherapeuticsMD Narrows 2025 Loss, Advances Royalty Strategy - TipRanks
TXMD Reports $7.5 Million in Cash Holdings as of Year-End 2025 - GuruFocus
TXMD: Net loss narrowed and license revenue surged as strategic alternatives are explored - TradingView
TXMD: 2025 saw improved results from royalty revenue, but litigation and liquidity risks threaten viability - TradingView — Track All Markets
TherapeuticsMD (NASDAQ: TXMD) reports 2025 results, weighs strategic options - Stock Titan
[10-K] TherapeuticsMD, Inc. Files Annual Report - Stock Titan
TXMD Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
TherapeuticsMD, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Therapeuticsmd Inc (TXMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.09%
3.08%
자본화:
|
볼륨(24시간):